[|Although I agree that in different families with psoriasis the genes
involved are different, form the main point of the genetics in
psoriasis should be made more clear: psoriasis is a polygenic disease,
i.e. within one patient there is a set of genes responsible for the
predisposition to psoriasis, which is different from that of another
patient, even in the same family.|auteur195]
[|The genetic aspects of psoriasis are well reviewed. From a personal perspective, having had the pleasure of working with Dr. Anne Bowcock, the discoverer of PSORS2 gene on chromosome 17 in 1994, for the past 14 years, I have always felt that the various phenotypic manifestations of psoriasis need to be carefully genotyped. Time needs to be spent in evaluating the genetics of these various psoriatic subtypes. In addition, there are obviously genetic associations with other immune-mediated diseases such as Crohn’s disease. Finally, is psoriatic arthritis truly a variation of psoriasis vulgaris as to date the genetics of the various forms of psoriatic arthritis remains to be fully elucidated. With the complexities of the phenotypic expressions in the skin, as well as the multiple variations of psoriatic arthritis, it is likely that the full genetic spectrum of psoriasis may take years to unravel.|auteur215]
Psoriasis is associated with familial involvement in 30 to 40% of cases. In patients whose illness starts during childhood, a strong linkage is noted between the disorder and certain HLA groups (CW6, CW7 and, less so, HLA B13, B17, B37, B38, B57, DR4 and DR7). In homozygous twins, one twin being affected goes hand in hand with the other being affected in 70% of cases. This concordance illustrates at once the existence of genetic predispositions and the triggering role of the environment.
By studying large families with psoriasis, it has been possible to detect chromosomal regions associated with the disease. These regions vary from one family to another, but three regions have been identified with some frequency by different teams: PSOR S1 on chromosome 6p, PSOR S2 on chromosome 17q and PSOR S3 on chromosome 4. Other regions have been identified: 1q21, 3q21, 4qter, 14q31-q32, 17q24-q25, 19p13.3 and 20p. Some of these regions represent genes of interest, like corneodesmosine, the key protein in desquamation, or a gene associated with the Crohn disease. Some of these chromosomal regions, particularly region 17q24-q25 (PSORS2), are currently arousing a quite special interest following the work of A.M. Bowcock. The genes in this region encode for a set of genes of the superfamily of immunoglobulins. Recently, in one psoriatic family, this researcher identified a gene and the corresponding protein that might be associated with the expression of the disease.
Whatever may be the interest of this research, one must not forget that the genes involved are probably different from one family to another, that most psoriasis are not familial and that there is no psoriasis gene, as some unscrupulous researchers have made believe to some families. Psoriasis must be clearly explained as being greatly different from the monogenic genetic diseases. In fact, given certain environmental conditions, it is likely that all the genotypes associated directly or indirectly with a significant increase of cytokinic expression in response to aggressions are capable of expressing themselves through different forms of psoriasis. It would be particularly interesting to be able to define groups of patients that belong to homogenous clinical phenotypes.
- 2019/08/12 Focus on...Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...News from our SPIN Columbian members
- 2019/05/21 Focus on...SPIN2019 is now available on your screen!
- 2019/04/18 Focus on...SPIN Congress 2019 in Paris coming soon
- 2019/04/17 Focus on...Do not miss Spin Congress 2019 highlights
News from the web office
- 2017/06/05PIN becomes SPIN - Skin Inflammation & Psoriasis International Network
- 2016/10/29PSO 2016 Congress - Webcasts Available!
- 2016/05/26PIN Survey on Phototherapy
- 2016/02/20PIN Study on Therapeutic Patient Education
- 2016/02/19World Directory of Psoriasis Medical Resources - February 2016 Update
- 2019/04/18 Focus on...SPIN Congress 2019 in Paris coming soon
- 2018/07/16SPIN Symposium at the Spring continental meeting - Tehran, 25-27 April 2018
- 2018/02/222nd National Meeting of the Egyptian Society for Psoriasis
- 2018/02/211st Psoriasis Symposium - Sarajevo 2017
- 2017/06/2815th São Paulo Meeting of Psoriasis and Vitiligo
News from medical groups
- 2018/04/183rd Turkish National Psoriasis Symposium
- 2017/06/21Brazilian Center for Psoriasis Studies joins SPIN!
- 2017/06/21Costa Rica Psoriasis Group - Meet them!
- 2017/02/02Works of the 1st Senegalese Psoriasis Day published!
- 2016/07/29Swiss S1 Guidelines for Systemic treatment of psoriasis vulgaris
News from patients associations
- 2017/02/08France Psoriasis - 2016 World Psoriasis Day
- 2016/05/26Senegal Patients Association joins PIN!
- 2015/08/04Epidermia Greece: a new partner association of PIN
- 2015/08/01Canadian Association of Psoriasis Patients joins PIN!
- 2015/04/09AEPSO Argentina launches digital map to find people with psoriasis in the country
Recent publications on Psoriasis and Atopic Dermatitis
JAK-inhibitors in dermatology: current evidence and future applications.
J Dermatolog Treat. 2019 Nov , 30, (7):648-658.
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such (...)see on pubmed
Patient preferences for attributes of topical anti-psoriatic medicines.
J Dermatolog Treat. 2019 Nov , 30, (7):659-663.
Patient preferences should be considered when prescribing topical treatments to drive up adherence and improve clinical outcomes. The aim of this work was to identify the most important attributes of topical medicines for psoriasis treatment in the patients' view, and explore the sociodemographic and clinical determinants of these preferences. A questionnaire for the evaluation of the relevancy given to specific attributes of topical medicines used for psoriasis treatment was developed (...)see on pubmed
Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation.
Redox Rep.. 2019 Dec , 24, (1):70-74.
To unveil the role of SIRT1 in limiting oxidative stress in psoriasis and to further discuss the therapeutic prospects of salidroside in psoriasis. Literature from 2002 to 2019 was searched with "psoriasis", "oxidative stress", "SIRT1", "salidroside" as the key words. Then, Oxidative stress in psoriasis and the role of SIRT1 were summarized and the potential role of salidroside in the disease was speculated. Oxidative stress might contribute to the pathogenesis of psoriasis. High levels (...)see on pubmed
A case of infective endocarditis associated with atopic dermatitis perioperatively treated with dupilumab.
J Dermatolog Treat. 2019 Nov , 30, (7):674-676.
Several case reports and reviews support a relationship between atopic dermatitis (AD) and infective endocarditis (IE). Here, we present a case of severe AD suspected of causing IE. A 21-year-old man with severe AD was admitted to our hospital due to unidentified fever, syncope, and headache. He was diagnosed with IE with cerebral embolism and mitral regurgitation. Before elective cardiac surgery, he was subcutaneously administered dupilumab for 2 months to control AD. Dupilumab improved (...)see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem. 2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)see on pubmed
Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Artif Cells Nanomed Biotechnol. 2019 Dec , 47, (1):3540-3547.
Allergen-specific immunotherapy is widely used for allergic rhinitis and asthma treatment worldwide. This study explored the efficacy and safety of sublingual immunotherapy (SLIT) with the extracts of ( Drops) on house dust mites (HDM)-induced atopic dermatitis (AD). 239 patients with HDM-induced AD were recruited and exposure to a multi-centre, randomized, double-blind, and placebo-controlled clinical trials for 36 weeks, which were randomly divided into placebo and sublingual Drops (...)see on pubmed